Apollon Wealth Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 191,845 shares of the biopharmaceutical company's stock after selling 10,183 shares during the period. Apollon Wealth Management LLC's holdings in Pfizer were worth $4,861,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of PFE. Clarity Asset Management Inc. acquired a new position in Pfizer during the 4th quarter worth about $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. North Capital Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $28,000. Bernard Wealth Management Corp. acquired a new stake in Pfizer in the 4th quarter valued at about $30,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on PFE shares. Jefferies Financial Group increased their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. BMO Capital Markets dropped their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Leerink Partners lowered their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. Citigroup lifted their target price on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer has an average rating of "Hold" and an average target price of $28.55.
Check Out Our Latest Research Report on Pfizer
Pfizer Price Performance
PFE stock traded down $0.02 during midday trading on Wednesday, hitting $24.59. 44,174,346 shares of the stock were exchanged, compared to its average volume of 41,947,842. The stock's 50-day moving average price is $23.99 and its 200-day moving average price is $24.77. The stock has a market cap of $139.79 billion, a price-to-earnings ratio of 17.82, a PEG ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.82 earnings per share. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.00%. Pfizer's dividend payout ratio (DPR) is 124.64%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
